Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cariprazine - Gedeon Richter

Drug Profile

Cariprazine - Gedeon Richter

Alternative Names: Cariprazine prolonged release; MP-214; REAGILA; Reagila; RGH-188; RGH-188 HCl; SYMVENU; Vraylar

Latest Information Update: 16 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gedeon Richter
  • Developer Allergan; Gedeon Richter; Mitsubishi Tanabe Pharma Corporation; Recordati
  • Class Antidepressants; Antipsychotics; Chlorobenzenes; Cyclohexanes; Piperazines; Small molecules; Urea compounds
  • Mechanism of Action Dopamine D2 receptor partial agonists; Dopamine D3 receptor partial agonists; Histamine H1 receptor antagonists; Serotonin 1A receptor partial agonists; Serotonin 2A receptor antagonists; Serotonin 2B receptor antagonists; Serotonin 2C receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar disorders; Schizophrenia
  • Registered Bipolar depression
  • Phase III Major depressive disorder
  • Phase I Schizoaffective disorder

Most Recent Events

  • 11 Sep 2019 Efficacy data and adverse events data from a phase IIIb trial in schizophrenia presented at the 32th Psychiatry Congress of the European College of Neuropsychopharmacology Congress (ECNP-2019 )
  • 25 Jul 2019 Cariprazine licensed to Hikma Pharmaceuticals in Bahrain, Egypt, Jordan, Iraq, Saudi Arabia, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Sudan, Syria and United Arab Emirates
  • 22 Jul 2019 Registered for Schizophrenia in Thailand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top